← Back to all trials
Recruiting
NCT07523438
Effect of Intranasal Dexmedetomidine on the Incidence of Emergence Agitation in Children Undergoing Strabismus Surgery
Conditions: Dexmedetomidine, Emergence Agitation
Sex: All
Ages: 3 Years – 6 Years
Healthy volunteers: No
Phase: NA
Enrollment: 150
Sponsor: Alexandria University
Location: Alexandria University Alexandria
Summary
Dexmedetomidine is a selective a-2 adrenergic agonist that provides sedative and analgesic effects. Intranasal dexmedetomidine has a slower and gradual onset compared to intravenous injection , with low incidence of nasal discomfort. Dexmedetomidine was tested at various doses and modes of administration, as well as different types of surgery and co-anesthetic drugs, as a single injection or continuous infusion. The authors have not agreed on the ideal clinical dose. The hypothesis is that intranasal dexmedetomidine 3mcg /kg will decrease the incidence of emergence agitation after strabismus surgery than dexmedetomidine 2 mcg/kg
Eligibility Criteria
Inclusion Criteria:
* Age: 3-6 years, both sexes
* ASA physical status class I , II.
Exclusion Criteria:
* history of neurological and psychiatric disease
* body mass index \> 20 kg m-2
* allergy to dexmedetomidine
* patients on medical treatment which has any sedative effect
* mentally retarded children
Source: ClinicalTrials.gov (NCT07523438). StuddyBuddy aggregates publicly available trial information.